Finn Guo on China’s Policy in Hemophilia Care: Patients Understand Patients Best
Finn Guo, Director of Information Research at Illness Challenge Foundation, shared on LinkedIn:
”Pleased to speak at the Central China Hemophilia Joint Conference today!
Leaders from patient organizations across the country gathered together.
In China, the reimbursement barrier for hemophilia has been largely resolved.
Thanks to the multi-layered insurance mechanism, most patients have achieved “0” out-of-pocket treatment costs.
Yet several critical challenges remain:
1. Prophylactic treatment (especially regular factor prophylaxis) is still severely under-covered
2. Some innovative therapies are not yet included in the NRDL (National Reimbursement Drug List), leaving patients to pay 100% out-of-pocket
3. Gene therapy for hemophilia B, just approved in China, is still far from being truly accessible to patients
When there is a huge information gap between patients’ lived reality and policymakers, it’s hard for decision-makers to truly understand what patients go through every day—and therefore hard for them to respond with precise, impactful policies.
“Patients understand patients best.”
Our mission is to build a bridge—to translate “patient language” into “policy language,” so that government, health insurance authorities, pharmaceutical companies, and all stakeholders can truly hear, see, and feel the real situation of patients.
Under this situation, the PED is the most powerful and authentic advocacy material.”

Stay updated with Hemostasis Today.
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026
-
Jul 13, 2026, 17:39Pascal Boulanger: Send a Postcard to Your Lab Staff From ISTH 2026
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026